Skip to content

US · ZSTK · MEDICAL - DISTRIBUTION

ZeroStack Corp. (ZSTK) intrinsic value and stock valuation

$2.58as of 2026-11-21 · Mkt cap 1.95M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ZeroStack Corp. DCF and intrinsic value

InvestorsCraft values ZSTK with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ZSTK’s statements →

ZeroStack Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Distribution Toronto, ON M5H 3Y2 zerostack.ai

How the business is doing

Fiscal 2019–2025, USD

Revenue
$35.7M+217.8% 5y CAGRd
20192025
Net income
-$-120.85M
20192025
Free cash flow
-$-8.8M
20192025
Total equity
$70.6M+34.1% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$35.7M$59.5M$76.1M$33.4M$8.98M
Operating income-$-9.56M-$-15.64M-$-50.35M-$-47.22M-$-19M
Net income-$-120.85M-$-15.91M-$-57.04M-$-52.41M-$-21.25M
EPSd-$-43.95M-$-49.72M-$-300.21M-$-524.1M-$-265.63M
Operating cash flow-$-8.68M-$-5.03M-$-8.4M-$-15.94M-$-20.65M
Capital expenditure-$-130K-$-130K-$-160K-$-1.29M-$-3.98M
Free cash flow-$-8.8M-$-5.17M-$-8.56M-$-17.23M-$-24.63M
Total assets$130.2M$26.2M$23.6M$81M$85.5M
Total debt$53.9M$4.9M$3.67M$3.76M$1.34M
Net debt$48.3M-$-1.12M-$-680K-$-5.17M-$-36.28M
Total equity$70.6M$4.51M$6.4M$56.4M$76.9M
Cash and short-term investments$5.62M$6.02M$4.35M$8.94M$37.6M
Income statement
20252024202320222021
Revenue$35.7M$59.5M$76.1M$33.4M$8.98M
Cost of revenue$40.5M$47M$58.3M$20.2M$6.55M
Gross profit-$-4.82M$12.5M$17.7M$13.3M$2.42M
Research and development expenses$240K$420K$60K$390K$130K
Selling, general and administrative expenses$1.21M$23.1M$23.3M$28.8M$17.8M
Other expenses$3.29M$4.65M$44.7M$31.3M$3.54M
Operating expenses$4.74M$28.1M$68.1M$60.5M$21.4M
Cost and expenses$45.2M$75.2M$126.4M$80.6M$28M
Interest income$0.00$0.00$0.00$30K$0.00
Interest expense$200K$210K$90K$0.00$30K
Depreciation and amortization$580K$770K$2.33M$2.63M$500K
Ebitda-$-8.98M-$-15.1M-$-45.87M-$-17.87M-$-20.93M
Operating income-$-9.56M-$-15.64M-$-50.35M-$-47.22M-$-19M
Total other income/expenses, net-$-105.79M-$-440K$2.06M-$-890K-$-2.46M
Income before tax-$-115.35M-$-16.08M-$-48.3M-$-48.11M-$-21.46M
Income tax expense$60K-$-180K-$-1.63M-$-1.41M-$-100K
Net income-$-120.85M-$-15.91M-$-57.04M-$-52.41M-$-21.25M
Weighted average shares outstanding$2.75M$320K$190K$100K$80K
Weighted average diluted shares outstanding$2.75M$320K$190K$100K$80K
Balance sheet
20252024202320222021
Cash and short-term investments$5.62M$6.02M$4.35M$8.94M$37.6M
Net receivables$800K$7.3M$7.1M$8.96M$5.6M
Inventory$1.9M$5.77M$8.51M$8.75M$3.03M
Total current assets$8.72M$19.8M$21.4M$31.2M$47.9M
Property, plant and equipment, net$510K$1.61M$1.24M$3.34M$4.98M
Goodwill and intangible assets$0.00$4.75M$950K$41.1M$29.8M
Long-term investments$121M$0.00$0.00$730K$2.67M
Total non-current assets$121.5M$6.46M$2.26M$49.8M$37.5M
Total assets$130.2M$26.2M$23.6M$81M$85.5M
Accounts payable$2.33M$5.46M$5.11M$7.83M$2.42M
Short-term debt$2.88M$2.87M$2.73M$2.2M$430K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.63M$18.8M$16.3M$17.5M$6.12M
Long-term debt$51.1M$2.03M$940K$1.56M$910K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$51.1M$2.88M$940K$7.13M$2.42M
Capital lease obligations$280K$2.82M$1.74M$2.68M$1.32M
Total liabilities$59.7M$21.7M$17.2M$24.6M$8.54M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-277.79M-$-158.14M-$-142.55M-$-90.86M-$-38.54M
Accumulated other comprehensive income (loss)$180K-$-220K-$-140K-$-2.73M-$-1.11M
Total equity$70.6M$4.51M$6.4M$56.4M$76.9M
Total investments$121M$0.00$0.00$730K$2.67M
Total debt$53.9M$4.9M$3.67M$3.76M$1.34M
Net debt$48.3M-$-1.12M-$-680K-$-5.17M-$-36.28M
Cash flow statement
20252024202320222021
Net income-$-4.42M-$-15.91M-$-47.36M-$-52.63M-$-21.36M
Depreciation and amortization$580K$770K$2.48M$2.63M$770K
Stock-based compensation$1.21M$2.78M$1.59M$3.4M$1.34M
Change in working capital$2.42M$3.15M-$-660K$3.82M-$-5.04M
Accounts receivable-$-350K-$-690K$1.52M$140K-$-5.69M
Inventory-$-50K$1.32M$580K$1.22M-$-1.14M
Accounts payable$3.16M$1.79M$0.00$1.09M$3.05M
Net cash provided by operating activities-$-8.68M-$-5.03M-$-8.4M-$-15.94M-$-20.65M
Investments in property, plant and equipment-$-130K-$-130K-$-230K-$-1.29M-$-3.98M
Acquisitions, net$460K$60K-$-70K-$-14.51M-$-8.09M
Net cash used for investing activities-$-3.46M$200K-$-230K-$-15.8M-$-14.55M
Common stock issued$14.5M$7.5M$2.74M$5M$42.6M
Common stock repurchased$0.00$0.00$0.00-$-260K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$11.4M$6.49M$3.15M$4.41M$58.1M
Net change in cash$370K$1.67M-$-4.55M-$-28.08M$22.1M
Cash at end of period$5.62M$6.05M$4.38M$9.54M$37.6M
Operating cash flow-$-8.68M-$-5.03M-$-8.4M-$-15.94M-$-20.65M
Capital expenditure-$-130K-$-130K-$-160K-$-1.29M-$-3.98M
Free cash flow-$-8.8M-$-5.17M-$-8.56M-$-17.23M-$-24.63M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ZeroStack Corp.

        ZeroStack Corp., through its subsidiary, Phatebo GmbH, engages in the pharmaceutical distribution business in Germany. It operates through Commercial & Wholesale and Digital Assets segments. The company distributes a range of pharmaceutical goods and medical products to treat various health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. It also operates as a decentralized AI treasury company that invests in the future of AI infrastructure through strategic ownership of 0G tokens. In addition, the company invests in early-stage companies. The company was formerly known as Flora Growth Corp. and changed its name to ZeroStack Corp. in January 2026. ZeroStack Corp. was incorporated in 2019 and is based in Toronto, Canada.

        CEO
        Daniel Reis-Faria
        Employees
        21
        Beta
        1.83

        Explore

        Frequently asked questions

        What is the intrinsic value of ZeroStack Corp. (ZSTK)?

        ZeroStack Corp. (ZSTK) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ZSTK undervalued?

        ZSTK trades at a price of $2.58 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.